Concerns about administering live, attenuated influenza vaccine (LAIV) in children with asthma “may not be warranted,” concluded authors of a study presented at IDWeek.
IDWeek 2015: Pediatric Infectious Disease
For treatment of uncomplicated, outpatient urinary tract infection (UTI), fewer failures were seen with empiric cephalexin than with trimethoprim/sulfamethoxazole (TMP-SMX) or amoxicillin, researchers presented at IDWeek 2015.
Children with uncomplicated cellulitis may be safely treated at home, as they are unlikely to have bacteremia, Laila F. Ibrahim, MBBChBAO, from the Royal Children’s Hospital @ Home Department in Parkville, Australia, reported at IDWeek 2015.
Introduction of early childhood immunization with the pneumococcal conjugate PCV13 vaccine has rapidly reduced the incidence of pediatric consolidated pneumonia (CP) cases in Argentina, according to findings from a prospective single-municipality population-based study reported at IDWeek 2015.
Even though probiotics are frequently administered in pediatric intensive care units (ICUs), incidence of probiotic-associated bacteremia appears to be low, authors of a single-institution case-control study reported at IDWeek 2015.
Monthly intranasal mupirocin prophylaxis in the neonatal intensive care unit (NICU) dramatically decreased healthcare-associated transmission of methicillin-resistant Staphylococcus aureus (MRSA) infections by 43% and cut invasive staphylococcal infections by 73%, according to a study presented at IDWeek 2015.
Adding routine probiotic prophylaxis in neonatal intensive care units (NICUs) is protective against necrotizing enterocolitis and bloodstream infections among extremely low birth weight (ELBW) infants, and improves their survival rates following necrotizing enterocolitis, according to authors of a multicenter quasi-experimental study in Germany.
A daily dose of intravenous gentamicin or tobramycin 9mg/kg achieved a safe and effective target Cmax range of 16-25mg/L in a pediatric population, a pharmacokinetic (PK) validation study presented at IDWeek 2015 concluded.
The humanized monoclonal antibody palivizumab has up to 58% effectiveness for reducing hospitalizations for severe Respiratory Syncytial Virus (RSV)-associated acute lower respiratory tract infections (aLRTI), suggest findings from a multicenter study reported at IDWeek 2015.
Preterm infants who do not receive respiratory syncytial virus immunoprophylaxis (RSV IP) frequently suffer severe RSV infection and ICU admission, according to findings reported at IDWeek 2015 from the observational multi-institutional SENTINEL 1 study.
Want to read more?
Please login or register first to view this content.